ロード中...

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

Raltegravir (MK-0518) is the first integrase (IN) inhibitor to be approved by the US FDA and is currently used in clinical treatment of viruses resistant to other antiretroviral compounds. Virological failure of Raltegravir treatment is associated with mutations in the IN gene following two main dis...

詳細記述

保存先:
書誌詳細
主要な著者: Delelis, Olivier, Malet, Isabelle, Na, Li, Tchertanov, Luba, Calvez, Vincent, Marcelin, Anne-Genevieve, Subra, Frederic, Deprez, Eric, Mouscadet, Jean-François
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2009
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2651800/
https://ncbi.nlm.nih.gov/pubmed/19129221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nar/gkn1050
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!